THE DISEASE
Transmissible spongiform encephalopathies (TSEs) are neurodegenerative diseases characterized by spongiform changes, neuronal death, astrocytosis, and accumulation of the pathological protein PrP Sc (the "scrapie form" of PrP) in the brain and to a lesser extent in other organs. TSEs are by definition transmissible, although this criterion may be difficult to establish in some cases.
The most common human TSE, or prion disease, is Creutzfeldt-Jakob disease (CJD). Epidemiologically, CJD is classified as sporadic (sCJD), familial (fCJD), iatrogenic (iCJD), and variant (vCJD). Even the most frequent form, sCJD, is very rare. It appears to be evenly distributed worldwide; countries that carry out surveillance report, quite uniformly, an incidence of ∼0.6-1.2 × 10 −6 per year (1). No exogenous or endogenous causes of sCJD have been identified yet. An endemic form of CJD, designated Kuru, occurred among the Aborigines in Papua New Guinea throughout the 1950s and 1960s. Kuru was horizontally transmitted by cannibalistic rituals and has not been observed in individuals born after cannibalism was abandoned (2).
WEISSMANN AGUZZI
Familial forms of CJD are transmitted as autosomal dominant traits and invariably cosegregate with mutations in PRNP, the gene that encodes the prion protein (3). Although experimental evidence from the mouse implies a role of additional factors (4-7), no genetic loci other than PRNP have been implicated in the pathogenesis of human prion diseases.
Several hundred cases of iCJD have been reported in recent decades. These have been attributed mainly to transplantation of tissues or administration of hormones derived from deceased individuals suffering from unrecognized TSEs, and, to a lesser extent, to the use of contaminated instruments in neurosurgical interventions. Infection by contaminated hormones was effectively eliminated when recombinant-peptide hormones replaced natural hormones in the mid-1980s, but individual patients are developing the disease even now-owing to the long incubation times involved.
Recently a patient developed vCJD after receiving a blood transfusion derived from another vCJD patient (8) . Another transfusion recipient died of unrelated causes but was found at autopsy to harbor PrP Sc in his lymphoid system (8a). Although it cannot be formally excluded that both patients developed prion disease independently, it is very likely that these cases represent the first identified instances of blood-borne CJD transmission (9) .
Biochemical and histopathological evidence suggests that vCJD represents transmission of bovine spongiform encephalopathy (BSE) prions to humans (10) (11) (12) . The incidence of vCJD in the United Kingdom rose each year from 1996 to 2001 (http://www.doh.gov.uk/cjd/cjd stat.htm), evoking fears of a large upcoming epidemic. Since then, however, the incidence of vCJD in the United Kingdom appears to be stabilizing and may even be falling. Hence there is hope that the total number of vCJD victims will be smaller than originally feared (13) .
In Switzerland, CJD has been a statutory notifiable disease since December 1987. A National Reference Center for Prion Diseases was established in 1995. Between 1996 and 2000, the incidence of CJD oscillated between 1.3 × 10 −6 and 1.4 × 10 −6 per year. However, in 2001 and 2002 the incidence was 2.6 × 10 −6 per year (14) , and this level appears to have been maintained through 2003 (15) . The cause of this apparent surge in incidence is unknown; beside statistical fluctuations, TSEs of iatrogenic or zoonotic origin have been discussed. It is also plausible that an "awareness bias" may be contributing, at least in part, to the increased CJD reporting.
Genetics and the Incidence of CJD
While all fCJD cases cosegregate with PRNP mutations, it is possible that some PRNP mutations cause neurodegenerative disease that is not transmissible and therefore represents a proteinopathy rather than a prion disease. Many such instances have been described in the mouse (23) and are exemplified by the "octapeptide repeat expansion" mutants of both mouse (24) and man (25, 26) .
Beside disease-causing mutations, PRNP may also comprise polymorphisms that have a profound effect on susceptibility to prion disease. Thus, all clinical cases of vCJD have the met/met rather than the val/val or met/val configuration at position 129 (27, 28) . However, recently subclinical vCJD was diagnosticized post mortem in a patient with met/val heterozygosity who died of other causes, showing that infection is certainly possible in this genotype but that progression to clinical disease may be very much slower than in met/met homozygotes (8a) . Humans heterozygous at position 129 are largely protected from CJD; this effect is so important that it may have exercised selective evolutionary pressure (29) . A lys rather than a glu residue at position 219 is thought to be protective against sCJD (30).
However, it is becoming increasingly apparent that genetic susceptibility markers and modifiers are not limited to the known polymorphisms in the PrP-encoding reading frame, as revealed by the identification of several quantitative trait loci that affect incubation time in the mouse (4-7). It is not clear what these modifiers might be. The possible protective effect against vCJD of a certain MHC class II constellation (31) has been disputed (32). Nonetheless, based on all that is known about the critical role of the immune system in peripheral prion infection (33), immunity-controlling genes are likely to feature among endogenous modifiers.
A large proportion of the British population may have been exposed to BSE infection. Animal experiments indicate that the infectious dose (ID 50 ) for oral cross-species transmission of BSE is relatively low [500 mg of brain tissue sufficed to cause disease in sheep (34)], yet only ∼150 humans have contracted vCJD. Thus, it is likely that vCJD susceptibility is controlled by endogenous and/or exogenous factors other than the amount of infectious agent ingested (35).
324

WEISSMANN AGUZZI
Extraneural PrP
Sc
Refinements in the technologies for detection of PrP
Sc have prompted a renaissance of studies of the distribution of the disease-associated prion protein in extracerebral organs. These studies in sCJD patients revealed that extraneural PrP Sc is more widespread than previously thought. Zanusso and colleagues found that PrP Sc is readily detectable in the olfactory mucosa of sCJD patients (36). Glatzel et al. found that approximately one third of the Swiss sCJD patients display PrP Sc in their skeletal muscle and another third (partially overlapping) have PrP Sc in lymphoid organs (19) . Further investigations are under way to determine whether these findings are universally valid for CJD patients or whether they are specific to the Swiss CJD cohort. If the latter were true, one might speculate that the peripheral presence of CJD in Swiss patients points to a specific etiology.
In vCJD, it has been appreciated for several years that substantial amounts of PrP Sc are detectable in lymphoid organs, and tonsil biopsies often suffice to firmly establish the diagnosis (18) . It remains to be established whether PrP Sc is present in skeletal muscle and other extraneural tissues of vCJD patients. The UK vCJD cases are likely to be primary transmissions from cattle with BSE. However, experimental transmission studies show that TSE strain characteristics can change upon serial passages after the original primary transmission (37). Therefore, horizontal vCJD transmission among humans could result in a different phenotype than zoonotic vCJD. This scenario calls for innovative studies to develop and validate classical and emerging tools for up-to-date prion strain typing.
THE NATURE OF THE INFECTIOUS AGENT
It is widely (though not universally) accepted that the TSE agent, or prion, is not a typical microorganism like a bacterium or virus, consisting of agent-specific nucleic acid that encodes one or more agent-specific proteins; rather, it may consist of a misfolded host protein, perhaps associated with other components. Notably, prion infection elicits no immune response.
One of the most striking and characteristic features of TSE is the deposition, mainly in the brain but also in other tissues, of a partially protease-resistant protein designated PrP Sc or PrP-res, which is a beta-sheet-rich conformational isomer of the protease-sensitive, alpha-helix-rich ubiquitous host protein PrP C . Biochemical and genetic evidence link PrP and its gene to the disease. PrP Sc copurifies with infectivity and vice versa. Familial forms of CJD are invariably linked to mutations in the PrP gene, and mice with disabled PrP genes are resistant to prion disease and fail to propagate the agent (for a review see Reference 23) . By and large, the available data and the failure to identify a disease-specific nucleic acid support the "protein-only" hypothesis. As enunciated by Prusiner, 
PATHOGENIC MECHANISMS IN PRION DISEASES
The damage wrought by prions is mainly evident in the central nervous system (CNS), although pathological changes in the spleen of nonhuman primates have also been noted (C. Lasmezas, personal communication). Because PrP Sc accumulates in the CNS and in some instances is deposited as an amyloid, it has been indicted as the toxic entity that causes neuronal apoptosis and elicits disease. The finding that peptides derived from PrP region 106-126 form aggregates and are toxic to cultured neuronal cells (48, 49) has been adduced in support of this contention, although the reproducibility of the phenomenon has been disputed (50). It is, however, not evident that the pathogenicity of the oligomerized peptides on cultured cells mimics the properties of PrP Sc accumulating in the CNS. PrP Sc produced by a prion-infected, PrP-expressing neuronal graft in the brain of PrP knockout mice did not cause disease, nor did it result in damage to neighboring neuronal tissue devoid of PrP (51). In addition, prion-infected mice carrying only a single PrP allele and producing half the wild-type level of PrP do not exhibit disease until about 450 d after intracerebral inoculation, in contrast to 150 d in wild-type mice, although they accumulate levels of PrP Sc similar to those of wildtype animals by 150 d after infection (52). Finally, depletion of PrP C in neurons of prion-infected mice by conditional knockout some weeks after prion inoculation prevents clinical disease despite massive accumulation of PrP Sc and infectivity in and around astrocytes (53). Therefore, PrP
Sc is likely to be responsible for CNS pathology only in neurons that express PrP C .
Gain of toxic function by a PrP moiety other than PrP
Sc is a distinct possibility. Over several years, a lively debate has unfolded on the role of abnormal PrP C topologies. Targeting of PrP to the cytosol was reported to result in rapidly lethal neurodegeneration (albeit without accumulation of PrP Sc ), and proteasome inhibition induces a slightly protease-resistant, cytoplasmic PrP species in cultured cells (54, 55). Therefore, prion toxicity was proposed to start with retrotranslocation of PrP C from the endoplasmic reticulum to the cytosol, in conjunction with impaired proteasomal function. However, others have found that cytosolic PrP retains its secretory leader peptide and does not contain a glycosyl phosphatidyl inositol anchor, suggesting that it never enters the endoplasmic reticulum (56) . Moreover, the toxicity of cytosolic PrP has been contested (57, 58 
SPREAD OF PRIONS
Prion pathogenesis can be broken down into spatially and temporally distinct phases: (a) infection and peripheral replication, (b) migration from the periphery to the CNS (neuroinvasion), and (c) neurodegeneration. The resistance to prions of mice that lack PrP C expression is amply documented (51, 61-63). PrP C expression is required for transporting the infectious agent from the peripheral sites to the CNS (as monitored by PrP C -expressing neurografts) (64) and within the CNS (65 (64, 66) . This finding suggests that hematopoietic cells transport prions from the entry site to the lymphoreticular system, which accumulates and replicates prions, but that PrP C expression in an additional compartment, presumably the peripheral nervous system, is required. B lymphocytes (not necessarily expressing PrP C ) are crucial for peripheral prion spread and neuroinvasion (67, 68) .
The dependence on lymphotoxin (LT)-mediated signaling by B cells may explain-at least in part-the requirement for B cells in peripheral pathogenesis. Follicular dendritic cells (FDCs) accumulate PrP Sc following scrapie infection (69) , and maturation of FDCs requires signaling by B cells that express LTα/LTβ trimers on their surface. Indeed, blockade of LTβ signaling via administration of soluble LTβR-Ig ablates mature FDCs and significantly impairs neuroinvasion and accumulation of peripheral PrP Sc and infectivity (70, 71) . FDCs are crucial to disease progression after oral scrapie challenge, but only within a short time window (72, 73) .
FDCs play a role in antigen trapping and in binding opsonized antigens to the CD21/CD35 complement receptors. Two studies have demonstrated that the complement system is relevant to prion pathogenesis. Mice genetically engineered to lack complement factors (74) or mice depleted of the C3 complement component (71) exhibited enhanced resistance to peripheral prion inoculation. Because FDCs are most likely immobile cells, they are unlikely to be responsible for prion transport into the CNS.
But just which cell types are involved in neuroinvasion? The innervation pattern of lymphoid organs is primarily sympathetic (75) . Sympathectomy delays the onset of scrapie, whereas sympathetic hyperinnervation enhances splenic prion replication and neuroinvasion, suggesting that innervation of secondary lymphoid organs is the rate-limiting step to neuroinvasion (76) . Although there is no physical contact between FDCs and sympathetic nerve endings (77) , the distance between FDCs and splenic nerves affects the velocity of neuroinvasion (78) . It remains to be determined whether this results from passive diffusion of prions or whether mobile cells (e.g., germinal center B cells) are involved in an active transport process.
Oral Prion Uptake
Upon oral challenge, an early rise in prion infectivity occurs in the distal ileum of infected organisms. This has been observed in several species but most extensively investigated in sheep. Western blot analysis has shown that Peyer's patches accumulate PrP Sc . This is true also in the mouse model of scrapie, where administration of mouse-adapted scrapie prions (RML strain) induces a surge in intestinal prion infectivity as early as a few days after inoculation (73, 79, 80) . Indeed, immune cells are crucial to the process of neuroinvasion after oral application. Mature FDCs, located in Peyer's patches, may be critical for the transmission of scrapie from the gastrointestinal tract (79) .
Myeloid dendritic cells may be involved in the transport of infectious agent by this process, and in fact recent work has implicated dendritic cells as potential vectors of prions in oral (81) and hematogenous (82) spread of the agent. It is equally possible, however, that lymphatic colonization is followed by direct entry of prions into nerve terminals.
ACTIVE AND PASSIVE VACCINATION
It was reported early on that anti-PrP antiserum reduces the titer of infectious hamster brain homogenates about a hundredfold (83) . Anti-PrP antibodies were found to inhibit formation of protease-resistant PrP in a cell-free system (84) . Also, antibodies (85, 86) and F(ab) fragments directed against PrP (87) can suppress prion replication in cultured cells.
These data suggest the feasibility of antiprion immunoprophylaxis, which could be implemented as passive immunization (transfer of antibodies) or active immunization (administration of antigens as vaccines). Active immunization is generally more effective, but it is exceedingly difficult to elicit humoral immune responses, because the mammalian immune system is largely tolerant of PrP of the same species. Mice devoid of PrP (88) show no tolerance and are highly susceptible to immunization with recombinant PrP (63) or PrP C -expressing cells (65) . Tolerance is typically brought about by activation-induced cell death, which is incurred by B or T lymphocytes undergoing very strong cross-linking of their antigen receptors. To determine whether the resilience of wild-type mice to antiprion immunization is attributable to the T-or B-cell compartment, transgenic mice were generated that expressed an immunoglobulin/B-cell receptor µ chain containing the epitope-interacting region of 6H4, a high-affinity anti-PrP monoclonal antibody (89) . The transgenic µ chain associated with endogenous κ and λ chains; some pairings led to reactive moieties and, consequently, to anti-PrP , which suggests that clonal deletion was actually occurring. B-cell clones with the highest affinity to PrP C are probably eliminated by tolerance, whereas clones with medium affinity are retained. The latter sufficed to block prion pathogenesis upon intraperitoneal prion inoculation (90) . Hence, B cells are not intrinsically tolerant of PrP C , and canin principle-mount a protective humoral response against prions. It was subsequently found that passive transfer of anti-PrP monoclonal antibodies (in admittedly heroic amounts) delays the onset of scrapie in mice infected with prions by intraperitoneal inoculation but is ineffective in mice infected by intracerebral inoculation (91), perhaps because insufficient levels of antibody are reached in the brain.
Although transgenic immunization provides an encouraging proof of principle, it cannot easily be reduced to practice. Passive immunization failed to confer protection if treatment was started after the onset of clinical symptoms, so it might be a better candidate for prophylaxis than for therapy of TSEs. Active immunization may be more effective, as in most antiviral vaccines, but it is rendered exceedingly difficult by the tolerance to PrP C (92, 93) . A recent report outlines a potentially serious obstacle to prion immunotherapy. Intracerebral injection of anti-PrP antibodies specific to certain epitopes at high concentrations provoked degeneration of hippocampal and cerebellar neurons (94) . Because monovalent Fab fragments did not elicit these responses, it is likely that crosslinking of PrP C by bivalent IgG antibodies is neurotoxic in vivo; perhaps it elicits some deleterious signaling event. Although these results add a cautionary note to the prospect of using antibodies against clinically overt prion diseases, it is possible that anti-PrP Fab fragments are capable of reducing infectious titers (87) without exerting a toxic effect (94) . Moreover, extraneural antibody administration may be useful for immunoprophylaxis of prion infections at early stages, before the agent reaches the brain.
Immunostimulation and Antiprion Prophylaxis
Cytidyl-guanyl oligodeoxynucleotides (CpG-ODN), which bind Toll-like receptor 9 (TLR9) and stimulate innate immune responses, were reported to delay disease upon chronic administration to scrapie-infected mice (95) . The contention that immune stimulation might protect against prions is difficult to reconcile with the observation that immune deficiencies of all kinds inhibit prion spread (67, 68, 74, 79, 96) . Besides, MyD88
−/− mice undergo normal prion pathogenesis despite abrogation of TLR9 signaling (97) . Hence, more detailed studies will be needed to reveal the basis of the antiprion effect of CpG-ODN. The fact that repeated administration of CpG-ODN can derange the architecture of lymphoid germinal centers, which are sites of prion replication, suggests that the antiprion effect of these compounds may rely on their immunosuppressive rather than their immunostimulatory properties (98) .
SEARCH FOR THERAPEUTIC AGENTS
Screening for putative therapeutic agents has been conducted at various experimental levels. Based on the assumption that PrP Sc is the infectious agent, or at least the pathogenic entity, compounds have been sought that in a cell-free system would stabilize PrP C , destabilize PrP Sc , or prevent conversion and thereby decrease the level of PrP Sc . Bis-ANS (4,4 -dianilino-1,1 -binaphthyl-5,5 -sulfonate) was described as potently inhibiting PrP aggregation (99) , and so-called β-sheet breaker peptides (100) and branched polyamines (101) partially disassembled PrP Sc to a protease-sensitive form. However, compounds identified by this type of screen, though potentially of interest, still face high hurdles to qualify as drug candidates: They must reach the appropriate cellular compartment; provide an acceptable therapeutic index (that is, ratio of toxic to therapeutic dose); exhibit pharmacokinetics that allow the build-up of a sufficiently high concentration in the biophase, which implies a capacity to cross the BBB effectively; and, last but not least, be accessible in sufficient quantity by chemical synthesis or from biological sources. No compounds have taken these hurdles so far.
A yeast-based screen has been reported in which the capacity of compounds to diminish the propagation of "yeast prions" is assessed (102) . Because the sequences of the yeast proteins involved are completely different from that of PrP, it is not clear how useful this screen will be to find compounds active on true prions.
A limited number of cell lines are susceptible to infection by prions (103) . Scrapie-infected cells, particularly the murine neuroblastoma-derived N2a line, have been used as targets for prospective drugs; the decrease of PrP Sc levels serves as a measure for therapeutic activity. The steady-state level of PrP Sc is determined by the rate of formation relative to that of degradation. Although originally thought to be very stable, PrP Sc in murine neuroblastoma cells has a half-life on the order of a day or so, and inhibition of its formation leads to its elimination within a few days. This is also the case after inhibition of PrP C synthesis, for example by siRNA (104), as well as sequestration or depletion of PrP C from the cell surface by binding of anti-PrP antibodies (85, 86) , Fab fragments (87), aptamers (105) , or compounds such as biquinoline (106) 
Accelerated degradation of PrP
Sc is attributed to its interaction with branched polyamines (101, 112) . Polyene antibiotics such as amphothericin B are believed to interact with detergent-resistant microdomains or rafts (113) and to inhibit generation of PrP Sc of at least some prion strains by interfering with the trafficking of PrP C (114) . Recently, a screen of 2000 compounds using scrapie-infected N2a cells yielded 17 candidates that were inhibitory to PrP Sc accumulation at 10 µM or less. Interestingly, only polyphenols were inhibitory in the cell-free conversion system (115) . However, none of these were active in a prion-infected mouse model (115a).
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Cell components other than PrP are believed to participate in or influence the conversion reaction, such as the laminin receptor precursor (LRP) (116) . Indeed, siRNA against LRP mRNA inhibits PrP Sc accumulation in scrapie-infected N2a cells (117) . A candidate for "protein X," postulated to play a role in the conversion process on the basis of genetic evidence (118), has not been identified so far.
A more stringent screen, mostly applied to compounds that are active in the cell-based assay, is provided by animal models, usually mice or hamsters. Animals are usually, but not always, poorly susceptible to prions from heterologous species. However, repeated passaging may overcome this species barrier, yielding mouseor hamster-adapted strains. Replacement of the endogenous PrP gene by the homologous gene of the prion donor may render mice susceptible to the foreign prions (119) . Thus, Prnp o/o mice transgenic for bovine or human PrP genes become susceptible to BSE and CJD prions, respectively (120) . Interestingly, however, some strains of wild-type mice are far more susceptible to human vCJD prions than are mice transgenic for the human PrP gene (37).
Drug candidates have been administered before, during, soon after, and long after inoculation with prions. For convenience they are usually given intraperitoneally (i.p.), but occasionally intracerebrally (i.c.) to overcome the BBB. A critical variable is the site of prion inoculation, which is usually i.p. or i.c., more rarely peroral. The i.p. route requires prion doses orders of magnitude higher than does i.c. inoculation, and incubation times are typically twice as long. The important consideration here is that i.p. or peroral prion inoculation provides a wide window of potential susceptibility to i.p. administration of drugs that are excluded from the CNS by the BBB. This window closes as neuroinvasion takes place.
Many compounds, representative examples of which are listed in Table 1 , prolong the incubation time in animals when administered before or soon after infection. Among these are sulfated polyanions (121) (122) (123) (124) (125) , Congo red D (126), polyene antibiotics (125, (127) (128) (129) , tetracyclic compounds (130) , and tetrapyrroles (111, 131, 132) . Copper added to the drinking water of scrapie-infected hamsters has been reported to delay clinical disease (133) , but a similar effect was reported for the copper chelator D-(-)-penicillamine in scrapie-infected mice (134); such is life in the prion field. None of the compounds tested in animal models were effective when administered peripherally after onset of clinical symptoms. However, when infused intraventricularly, pentosan polysulfate (PPS) at high levels extended the survival of mice and decreased PrP Sc deposition even when administered late after infection, while antimalarial drugs such as quinacrine showed no significant effect. At excessive doses, adverse effects such as hematoma formation were observed (135) . Intraventricular infusion of biquinoline derivatives also resulted in moderate extension of the survival period (106) .
A PrP-Fc 2 fusion protein that was found to compete with PrP C for PrP Sc had a protective effect against i.p. scrapie infection of mice when expressed from a transgene (136) . It will be interesting to determine whether PrP-Fc 2 is also active when delivered as a drug. If so, soluble prion protein mutants may represent useful prionostatic compounds.
TABLE 1
Representative compounds used in attempts at therapy of prion disease 
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ATTEMPTS AT HUMAN THERAPY
The earliest attempts to treat human prion disease, performed when the agent was generally assumed to be a virus, were carried out with antiviral drugs, such as amantadine, and were unsuccessful (137) .
Quinacrine
Quinacrine, chlorpromazine, and some tricyclic derivatives with an aliphatic side chain were described as efficient inhibitors of PrP Sc formation in murine neuroblastoma cells chronically infected with the Chandler scrapie isolate (138, 139) . Because quinacrine and chlorpromazine have been used in human medicine as antimalarial and antipsychotic drugs, respectively, and because they cross the BBB, they were proposed as therapeutic agents for CJD patients (139) . No therapeutic effect was seen following quinacrine treatment of 20 patients (140) (A. Alperovich, quoted in Reference 141), although some transient improvement occasionally occurred (142) . Subsequent animal experiments failed to demonstrate efficacy in the treatment of TSEs (141), even after intraventricular infusion (135) .
Amphothericin B
Amphothericin B and some of its analogues delayed the appearance of spongiosis, astrogliosis, and PrP Sc accumulation in the brain of scrapie-infected hamsters (125) . However, an attempt to treat a CJD patient with amphothericin B was unsuccessful (143) . In view of its high systemic toxicity, these results dampen any hopes that amphothericin B will prove useful in prion disease therapy.
Pentosan Polysulfate
Data presented at two prion meetings in 2002, and published recently (135) , suggest that intraventricular administration of PPS to intracerebrally prion-infected mice prolonged incubation time. PPS is marketed in some countries as a treatment for interstitial cystitis and as an anticoagulant, although its side effects include hemorrhage and hypersensitivity reactions.
ETHICAL CONSIDERATIONS
Recently a legal case was brought by two families whose children JS and PA, . They applied to the court to permit intraventricular administration of PPS, a treatment previously given only to rodents and dogs. The judge heard testimony from Doh-Ura, the Japanese researcher who had performed the animal studies; from a neurosurgeon willing to administer the novel treatment; and from several respected neurologists who expressed reservations about it. The judge found that both young patients had "some enjoyment from life which is worth preserving" and that the treatment, as it was supported by medical opinion, would be in their "best interest" (the legal criterion for doctors to treat patients who lack capacity for personal decisions) (144) . Treatment has been initiated, but no reports on the fate of the patients have been issued.
Physicians can thus come under pressure from the courts to allow new treatments to be used without having been tested in clinical trials, although the ruling described above implies that such decisions would have to withstand the "Bolam" test of being acceptable to a reasonable body of medical opinion. The ruling also upheld the application of the Human Rights Act in this area, citing Articles 2 and 8, the rights to life and to respect for family life. It is not inconceivable that such analysis could allow patients to circumvent clinical trials by asserting their rights to receive innovative therapy, and this development is of concern, particularly in the clinical field of human prion diseases.
We may at some stage be confronted with a therapy that can eradicate prion infection without reversing the neural damage, which in extreme cases could condemn patients to years or decades of severe disability and dementia. This would lead to an ethical dilemma as to whether treatment should be withheld if the disease has progressed to a severe stage. Such situations could be prevented if a diagnostic test could detect prion disease in its preclinical stage. Whether such a test, if it ever became available, would be applied to detect a disease with an incidence of 1 in a million per year is a matter of debate; clearly it would be practicable in the case of familial prion diseases.
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